What is the best drug for PDA?

Indomethacin: A Key Treatment for Patent Ductus Arteriosus

Patent ductus arteriosus (PDA) is a common condition in premature infants where the ductus arteriosus—the blood vessel connecting the pulmonary artery and aorta—fails to close after birth. When left untreated, it can lead to complications such as heart failure or respiratory issues. One of the most effective medical interventions for closing the PDA is indomethacin.

Indomethacin, a nonsteroidal anti-inflammatory drug (NSAID), works by inhibiting the production of prostaglandins—especially PGE₂—which are responsible for keeping the ductus open. By blocking these chemical messengers, indomethacin promotes constriction and closure of the vessel. Its effect is typically seen within minutes of administration, making it a fast-acting option in neonatal intensive care settings.

This medication is particularly useful in preterm infants, where the ductus is more sensitive to prostaglandin levels. While other drugs, like ibuprofen, are sometimes used, indomethacin remains a first-line choice in many neonatal units due to its proven efficacy and rapid onset. However, its use requires careful monitoring, as it can affect kidney function and cerebral blood flow in fragile newborns.

It’s important to note that while indomethacin promotes closure, not every PDA requires treatment—especially in full-term infants where spontaneous closure is more likely. The decision to treat depends on the infant’s overall clinical status, gestational age, and the size of the shunt.

In summary, indomethacin plays a vital role in managing symptomatic PDA in preterm infants by targeting the biological mechanism that keeps the ductus open. When used appropriately, it offers a non-surgical route to closure, supporting better outcomes in vulnerable newborns.